2. Academic Validation
  3. Triptolide attenuates irritable bowel syndrome via inhibiting ODC1

Triptolide attenuates irritable bowel syndrome via inhibiting ODC1

  • BMC Gastroenterol. 2023 Jun 12;23(1):202. doi: 10.1186/s12876-023-02847-8.
Ning Zhu # 1,  Liuyan Zhu # 2,  Xueliang Zhang 2,  Chengbin Huang 3,  Wenjun Xiang 4,  Bingwu Huang 5
Affiliations

Affiliations

  • 1 Department of Cardiology, The Third Affiliated Hospital of Shanghai University (Wenzhou People's Hospital), The Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, No. 299 Guan Road, Wenzhou, 325000, Zhejiang Province, People's Republic of China. [email protected].
  • 2 Department of General Practice, The Third Affiliated Hospital of Shanghai University (Wenzhou People's Hospital), The Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, No. 299 Guan Road, Wenzhou, 325000, Zhejiang Province, People's Republic of China.
  • 3 Department of Orthopedic Surgery, The Second Affiliated Hospital, Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Wenzhou, 325000, Zhejiang Province, People's Republic of China.
  • 4 Department of Pathology, The Third Affiliated Hospital of Shanghai University (Wenzhou People's Hospital), The Wenzhou Third Clinical Institute Affiliated to Wenzhou Medical University, No. 299 Guan Road, Wenzhou, 325000, Zhejiang Province, People's Republic of China.
  • 5 Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital, Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Wenzhou, 325000, Zhejiang Province, People's Republic of China. [email protected].
  • # Contributed equally.
PMID: 37308808 DOI: 10.1186/s12876-023-02847-8
Abstract

Background: Irritable bowel syndrome (IBS) is a chronic disorder of the gut-brain axis with significant morbidity. Triptolide, an active compound extracted from Tripterygium wilfordii Hook F (TwHF), has been widely used as a major medicinal herb in the treatment of inflammatory disease.

Methods: The chronic-acute combined stress (CAS) stimulation was used to establish IBS rat model. The model rats were then gavaged with triptolide. Forced swimming, marble-burying, fecal weight and abdominal withdrawal reflex (AWR) score were recorded. Pathologic changes in the ileal and colonic tissues were validated by hematoxylin and eosin staining. The inflammatory cytokines and Ornithine Decarboxylase-1 (ODC1) in the ileal and colonic tissues were performed by ELISA and WB.

Results: Triptolide didn't have antidepressant- and antianxiety- effects in rats caused by CAS, but decreased fecal weight and AWR score. In addition, Triptolide reduced the release of IL-1, IL-6, and TNF-α and the expression of ODC1 in the ileum and colon.

Conclusion: The therapeutic efficacy of triptolide for IBS induced by CAS was revealed in this study, which may be related to the reduction of ODC1.

Keywords

Inflammation; Irritable bowel syndrome; Ornithine decarboxylase 1; Triptolide.

Figures
Products